N-氨乙基哌嗪 、 甲酸甲酯 以
甲醇 为溶剂,
115.0~120.0 ℃
、1.78 kPa
条件下,
以151.6 g (48% of theory) of N-2-aminoethyl-N'-formylpiperazine were obtained at 0.1 mm Hg between 115 and 120° C. in the form of a yellowish liquid的产率得到4-(2-氨基乙基)-1-哌嗪甲醛
参考文献:
名称:
Formylpiperazinyl-(meth)acrylic acid derivatives for treatment of
2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors
申请人:KOLESNIKOV Aleksandr
公开号:US20090054432A1
公开(公告)日:2009-02-26
The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
本发明涉及新型 VIIa、IXa、Xa、XIa 因子的抑制剂,特别是 VIIa 因子的抑制剂,包括这些抑制剂的药物组合物,以及使用这些抑制剂治疗或预防血栓栓塞性疾病、癌症或类风湿关节炎的方法。本发明还公开了制备这些抑制剂的方法。
2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS
申请人:Kolesnikov Aleksandr
公开号:US20110269806A1
公开(公告)日:2011-11-03
The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
Die Erfindung betrifft neue Formylpiperazingruppen enthaltende (Meth)acrylsäureester und (Meth)acrylsäureamide (I) der allgemeinen Formel (I)
in der R¹, R² und X die in der Beschreibung angegebene Bedeutung haben und Zubereitungen (II) zur Verwendung als Adhäsivkomponente zur Behandlung kollagenhaltiger Materialien, die diese Verbindungen enthalten, Verfahren zur Herstellung und die Verwendung der Zubereitungen.
本发明涉及通式(I)的新的含甲酰哌嗪基团的(甲基)丙烯酸酯和(甲基)丙烯酸酰胺(I),其中R¹、R²和X的含义在描述中给出。
中 R¹、R² 和 X 的含义,以及用作处理含有这些化合物的含胶原蛋白材料的粘合剂成分的制剂 (II)、制备工艺和制剂的用途。